Fore Pharmas latest report ‘Global Ulcerative Colitis Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global ulcerative colitis drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the ulcerative colitis drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Ulcerative Colitis: Overview
- Ulcerative Colitis Drug Pipeline Overview
- Ulcerative Colitis Phase 3 Clinical Trial Drug Pipeline Insights
- Ulcerative Colitis Phase 2 Clinical Trial Drug Pipeline Insights
- Ulcerative Colitis Phase 1 Clinical Trial Drug Pipeline Insights
- Ulcerative Colitis Preclinical Research Drug Pipeline Insights
- Ulcerative Colitis Drug Discovery Pipeline Insights
- Geographic Landscape of Ulcerative Colitis R&D Activities
- Ulcerative Colitis R&D Activities in North America
- Ulcerative Colitis R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Ulcerative Colitis Drug Market

1. Ulcerative Colitis: Disease Definition
2. Ulcerative Colitis Drug Pipeline Overview
3. Ulcerative Colitis Phase 3 Clinical Trial Drug Pipeline Insights
4. Ulcerative Colitis Phase 2 Clinical Trial Drug Pipeline Insights
5. Ulcerative Colitis Phase 1 Clinical Trial Drug Pipeline Insights
6. Ulcerative Colitis Preclinical Research Drug Pipeline Insights
7. Ulcerative Colitis Drug Discovery Pipeline Insights
8. Geographic Landscape of Ulcerative Colitis R&D Activities
8.1 Ulcerative Colitis R&D Activities in North America
8.2 Ulcerative Colitis R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Ulcerative Colitis Drug Market

10 Research Methodology Table 1: Ulcerative Colitis Drug Pipeline: Phase 3 Clinical Trial
Table 2: Ulcerative Colitis Drug Pipeline: Phase 2 Clinical Trial
Table 3: Ulcerative Colitis Drug Pipeline: Phase 1 Molecules
Table 4: Ulcerative Colitis Drug Pipeline: Preclinical Research
Table 5: Ulcerative Colitis R&D Activities by Geography
Table 6: Ulcerative Colitis Drug Pipeline: North America
Table 7: Ulcerative Colitis Drug Pipeline: Europe
Table 8: Ulcerative Colitis Drug Pipeline: Licensing Activities

 Figure 1 : Ulcerative Colitis Drug Pipeline Molecules by Stages
Figure 2 : Ulcerative Colitis R&D Activities by Geography